COSMOS Pharmaceutical Corporation

3349.TJapan

20 filed reports · 233 financial concepts

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Revenue

¥1.1T

FY2026 · to May 31, 2026

up +8.7% vs ¥1.01T

Annual report

Net income

¥32B

FY2026 · to May 31, 2026

up +3.4% vs ¥31B

Annual report

Operating income

¥42.4B

FY2026 · to May 31, 2026

up +4.8% vs ¥40.4B

Annual report

Latest quarter

Revenue

¥287B

Q1 FY2027 · to Aug 31, 2026

up +5.2% vs ¥272B

Q1 report

Net income

¥8.25B

Q1 FY2027 · to Aug 31, 2026

up +1.0% vs ¥8.17B

Q1 report

Operating income

¥12B

Q1 FY2027 · to Aug 31, 2026

up +3.1% vs ¥11.6B

Q1 report

Filed reports

20 reports · Nov 2021 to Aug 2026

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Annual · annual securities reportEDINET51,889May 2022 to May 2026
Half Year · quarterly securities reportEDINET3546Nov 2021 to Nov 2023
Q1 · quarterly earnings release (kessan tanshin)EDINET3388Aug 2024 to Aug 2026
Q3 · quarterly securities reportEDINET3445Feb 2022 to Feb 2024
Half Year · half-year securities reportEDINET2440Nov 2024 to Nov 2025
Q1 · quarterly securities reportEDINET2296Aug 2022 to Aug 2023
Q3 · quarterly earnings release (kessan tanshin)EDINET2244Feb 2025 to Feb 2026

Documents

PeriodTypePeriod endPublishedFactsSource
FY2027 Q1quarterly earnings release (kessan tanshin)2026-08-312026-10-13161Open
FY2026annual securities report2026-05-312026-08-26643Open
FY2026 Q3quarterly earnings release (kessan tanshin)2026-02-282026-04-13155Open
FY2026 H1half-year securities report2025-11-302026-01-14268Open
FY2026 Q1quarterly earnings release (kessan tanshin)2025-08-312025-10-14129Open
FY2025annual securities report2025-05-312025-08-28314Open
FY2025 Q3quarterly earnings release (kessan tanshin)2025-02-282025-04-1489Open
FY2025 H1half-year securities report2024-11-302025-01-14172Open
FY2025 Q1quarterly earnings release (kessan tanshin)2024-08-312024-10-1198Open
FY2024annual securities report2024-05-312024-08-29315Open
FY2024 Q3quarterly securities report2024-02-292024-04-15175Open
FY2024 H1quarterly securities report2023-11-302024-01-15181Open

Financial data

233 concepts · 4,248 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

GAAP228 concepts · 4,168 facts · May 2020 to Aug 2026

  • EPS (Basic)50 · May 2020 to Aug 2026
  • Net Assets47 · May 2020 to Aug 2026
  • Total Assets47 · May 2020 to Aug 2026
  • Accounts payable - trade42 · May 2021 to Aug 2026
  • Accounts receivable - trade42 · May 2021 to Aug 2026
  • Asset retirement obligations-NCL42 · May 2021 to Aug 2026
  • Capital surplus42 · May 2021 to Aug 2026
  • Cash and deposits42 · May 2021 to Aug 2026
  • Construction assistance fund receivables42 · May 2021 to Aug 2026
  • Income taxes payable42 · May 2021 to Aug 2026
  • Intangible assets42 · May 2021 to Aug 2026
  • Investments and other assets42 · May 2021 to Aug 2026
  • Land42 · May 2021 to Aug 2026
  • Leasehold and guarantee deposits42 · May 2021 to Aug 2026
  • Long-term borrowings42 · May 2021 to Aug 2026
  • Merchandise42 · May 2021 to Aug 2026
  • Other-CA42 · May 2021 to Aug 2026
  • Other-CL42 · May 2021 to Aug 2026
  • Other-IOA42 · May 2021 to Aug 2026
  • Other-NCL42 · May 2021 to Aug 2026
  • Property, plant and equipment42 · May 2021 to Aug 2026
  • Provision for loss on store closings42 · May 2021 to Aug 2026
  • Retained Earnings (Accumulated Deficit)42 · May 2021 to Aug 2026
  • Revenue42 · May 2020 to Aug 2026

Guidance5 concepts · 80 facts · Oct 2024 to Oct 2026

  • EPS (Basic) Guidance16 · Oct 2024 to Oct 2026
  • Operating Income Guidance16 · Oct 2024 to Oct 2026
  • Ordinary Income Guidance16 · Oct 2024 to Oct 2026
  • Profit Attributable to Owners of Parent Guidance16 · Oct 2024 to Oct 2026
  • Revenue Guidance16 · Oct 2024 to Oct 2026

Segments

Figures broken down by business line, region, product or another axis the company reports on.

No segment breakdowns.

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of COSMOS Pharmaceutical Corporation (3349.T) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 20, 2026) and refreshed every few hours.